topical BRAF inhibitor (gel) for EGFRi rash

Ph. I in mCRC with EGFRi-related rash

paradoxical activ. of MAPK to counter EGFRi

Cancer Discovery, May 25, 2021

Lutris-Parma, Tel Aviv, IL / MSKCC, NY


The Lutris-Parma topical BRAF inhibitor, LUT014, is intended to treat rash caused by EGFR inhibitors. Rash is a significant and common side effect of EGFR inhibitor treatment leading to worse…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: